Lustro Comments

Discuss this Deal with other Investors


We use a new genetics platform to develop better vaccines for flu, COVID-19, etc

Claim My Business
Security Type
Convertible Note
Technology, Community & Lifestyle, Healthcare & Medical, Education
Min Investment
Pasadena, CA
Expected Close Date
April 29, 2024
Target Raise
No. Investors
Security Price
Number of Employees
Short Term Debt
Cost of Goods
Long Term Debt
Net Income

Key Deal Facts

Huge global market for these vaccines: Universal flu - $22B; COVID-19 - $5B Chance to make an enormous societal impact Patented durable and universal flu vaccine Major smashes: Moderna, BioNTech, Novavax: Invest in the next one! Backed by Life Science Angels - #1 US angel group (CB Insights), Sand Hill Angels, Tech Coast Angels Funded by the DoD and the NSF

Management Team / Advisory Board Bios

Arthur Young CEOPhD from a top 5-medical school, postdocs at Harvard and UCLA, pioneered a powerful new viral genetics platform, Olga Petrauskene DirectorProduced an HIV and flu diagnostic with Applied Biosystems that is sold in 60 countries, Justin Kern DirectorWrote a freelance article for Newsweek on vaccines that reached millions

Amount Raised : $129,283
Reveal the Score by Voting
Additional ratings from other users are needed to determine a viable CrowdScore for this deal.
The "CrowdScore" for this deal is determined by user ratings and other factors using our proprietary algorithm.
The overall viability and scalability of the business concept as well as the ability to drive the concept to profitability over time.
Business Idea
The progress made thus far in demonstrating that the business has viability, a customer base or other business traction.
Business Traction
The experience of the management team in running, scaling and/or exiting a business that required similar skills to execute the business plan.
Management Team
The value of the company compared to similar companies raising money from investors.

Security Description

A convertible security is a security that can be converted into another security, typically equity in the next round of financing.

Research Reports

No reports have been submitted

Become a Reporter